Erdélyi-Tóth V - Search Results

1

Pharmacokinetics of panomifene in healthy volunteers at phase I/a study.

Erdélyi-Tóth V, Gyergyay F, Számel I, Pap E, Kralovánszky J, Bojti E, Csörgo M, Drabant S, Klebovich I. Erdélyi-Tóth V, et al. Anticancer Drugs. 1997 Jul;8(6):603-9. doi: 10.1097/00001813-199707000-00008. Anticancer Drugs. 1997. PMID: 9300575 Clinical Trial.

2

[Endocrine effect of a new anti-estrogen compound (EGIS-5650, panomifene) in healthy volunteers: phase I/a study].

Számel I, Budai B, Gyergyay F, Erdélyi-Tóth V, Kralovánsky J, Drabant S, Csörgö M, Zsarnóczay P. Számel I, et al. Among authors: erdelyi toth v. Orv Hetil. 1994 May 15;135(20):1077-81. Orv Hetil. 1994. PMID: 7519764 Clinical Trial. Hungarian.

3

Determination of panomifene in human plasma by high-performance liquid chromatography.

Erdélyi-Tóth V, Pap E, Kralovánszky J, Bojti E, Klebovich I. Erdélyi-Tóth V, et al. J Chromatogr A. 1994 May 13;668(2):419-25. doi: 10.1016/0021-9673(94)80134-7. J Chromatogr A. 1994. PMID: 8032491

4

5-ethyl-2'-deoxyuridine, a modulator of both antitumour action and pharmacokinetics of 5-fluorouracil.

Kralovánszky J, Katona C, Jeney A, Pandi E, Noordhuis P, Erdélyi-Tóth V, Otvös L, Kovács P, Van der Wilt CL, Peters GJ. Kralovánszky J, et al. Among authors: erdelyi toth v. J Cancer Res Clin Oncol. 1999 Dec;125(12):675-84. doi: 10.1007/s004320050333. J Cancer Res Clin Oncol. 1999. PMID: 10592100

5

Pharmacokinetic studies on Elobromol in children with brain tumors.

Paál C, Erdélyi-Tóth V, Pap E, Csáki C, Ferencz T, Schuler D, Borsi JD. Paál C, et al. Among authors: erdelyi toth v. Anticancer Drugs. 1994 Oct;5(5):539-47. Anticancer Drugs. 1994. PMID: 7858286 Clinical Trial.

6

[Pharmacokinetic study of dibromodulcitol in children with brain tumors].

Paál K, Erdélyi-Tóth V, Pap E, Csáki C, Ferencz T, Schuler D, Borsi J. Paál K, et al. Among authors: erdelyi toth v. Orv Hetil. 1994 Nov 13;135(46):2527-34. Orv Hetil. 1994. PMID: 7800388 Hungarian.

7

Relation between dose, plasma concentration and toxicity in a phase I trial using high dose intermittent administration of an alkylating agent, diacetyldianhydrogalactitol (DADAG).

Kerpel-Fronius S, Erdélyi-Tóth V, Gyergyay F, Hindy I, Mechl Z, Nekulová M, Somfai-Relle S, Kovács P, Ujj G, Kanyár B, et al. Kerpel-Fronius S, et al. Among authors: erdelyi toth v. Cancer Chemother Pharmacol. 1986;16(3):264-8. doi: 10.1007/BF00293989. Cancer Chemother Pharmacol. 1986. PMID: 3698168

8

The role of comparative pharmacokinetics in the planning of human dose escalation: the experience with diacetyldianhydrogalactitol.

Kerpel-Fronius S, Erdélyi-Tóth V, Somfai-Relle S, Csetényi J, Kovács P, Ujj G, Kanyár B. Kerpel-Fronius S, et al. Among authors: erdelyi toth v. Cancer Chemother Pharmacol. 1988;22(2):109-13. doi: 10.1007/BF00257306. Cancer Chemother Pharmacol. 1988. PMID: 3409440

9

Solid-phase extraction of vinblastine and vincristine from plasma and urine: variable drug recoveries due to non-reproducible column packings.

Vendrig DE, Holthuis JJ, Erdélyi-Tóth V, Hulshoff A. Vendrig DE, et al. Among authors: erdelyi toth v. J Chromatogr. 1987 Feb 20;414(1):91-100. doi: 10.1016/0378-4347(87)80027-0. J Chromatogr. 1987. PMID: 3571394

10

Pharmacokinetic study in a phase I trial with an alkylating agent, diacetyldianhydrogalactitol (DADAG).

Erdélyi-Tóth V, Kerpel-Fronius S, Kanyár B, Eckhardt S. Erdélyi-Tóth V, et al. Cancer Chemother Pharmacol. 1986;16(3):257-63. doi: 10.1007/BF00293988. Cancer Chemother Pharmacol. 1986. PMID: 3698167

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

12 results

Search Page

Filters